After completing this course you’ll be able to:
| 1. | Define CKD. |
| 2. | List the five broad categories of GFR and briefly describe each. |
| 3. | Define GFR. |
| 4. | State why the serum creatinine is a poor estimator of GFR. |
| 5. | Describe the MDRD study equation and clinical trial. |
| 6. | List several factors other than kidney disease that can account for a low estimated GFR. |
| 7. | State the two important trends that will increase the number of ESRD patients in the future. |
| 8. | Discuss the finding of NHANES regarding racial disparities. |
| 9. | List the four patient groups at high risk for CKD. |
| 10. | List predisposing factors, initiating factors and progression factors of CKD. |
| 11. | Compare features of progressive CKD in type 1 and type 2 diabetic patients. |
| 12. | Describe the microalbumin test and what conditions result in false positive results. |
| 13. | List the three recommendations that those at high risk for diabetes should incorporate into their life style. |
| 14. | List the three points of the UKPDS regarding blood pressure control. |
| 15. | Describe the modifications of the DASH diet in stages 3 and 4 in CKD. |
| 16. | Define malignant hypertension. |
| 17. | Describe the AASK study. |
| 18. | Compare mortality of dialysis patients and the general population. |
| 19. | Describe smoking cessation and kidney disease. |
| 20. | List the five diagnostic traits of the metabolic syndrome. |
| 21. | List nontraditional risk factors for CVD and CKD. |
| 22. | State the preferred first line therapy for hypertension in patients with either diabetic or |
| 23. | Discuss the use of loop diuretics with hyperkalemia. |
| 24. | List factors that contribute to hyperkalemia. |
| 25. | Discuss albuminuria and macroalbuminuria. |
| 26. | State at what point a nephrologist should be consulted. |
| 27. | Discuss the incidence and cause of anemia in patients with CKD. |
| 28. | Compare Procrit and Aransep (Table 10.1). |
| 29. | List three reasons iron deficieincy is common in patients with CKD. |
| 30. | Discuss the abnormalities of calcium and phosphorous in CKD. |
| 31. | Discuss the role of Vitamin D in CKD. |
| 32. | Discuss the restriction of dietary phosphorous and phosphorous binding agents. |
| 33. | Compare Paracalcitrol and doxercalciferol. |
| 34. | State how the central nervous system is affected by acidosis. |
| 35. | Compare AVFs and AVGs. |
| 36. | Discuss dyslipidemia and cardiovascular disease in the CKD patient. |
| 37. | List and describe the three steps in drug dosing in the CKD. |
| 38. | Explain Medicare coverage for ESRD. |
| 39. | Describe the role of the primary care physician, nephrologist and other team members in |